Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Insys Therapeutics (INSY) Stock Price
News coverage about Insys Therapeutics (NASDAQ:INSY) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insys Therapeutics earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.1854191008584 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Ex-Insys employee’s lawyer does not need disqualified from bribe case: judge – Reuters (reuters.com)
- New Jersey will sue billionaire drug company CEO over opioids – NJ.com (nj.com)
- Billionaire founder of Insys to plead not guilty to opioid bribe scheme (uk.reuters.com)
- N.J. attorney general names Insys founder Kapoor as defendant in opioid false-claims lawsuit (philly.com)
Shares of Insys Therapeutics (NASDAQ INSY) opened at $5.37 on Friday. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.
INSY has been the topic of a number of recent analyst reports. Zacks Investment Research raised Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Wednesday, October 18th. Royal Bank Of Canada set a $8.00 price target on Insys Therapeutics and gave the company a “buy” rating in a report on Friday, October 27th. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Insys Therapeutics in a report on Monday, October 30th. Jefferies Group LLC reduced their target price on Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Finally, BidaskClub raised Insys Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Insys Therapeutics currently has an average rating of “Hold” and a consensus price target of $9.38.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.